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Acid Phosphatase: Clinical Utility of the First Tumor Markert 
Christopher J. DiPaolo, MD* and Jan Rival, MD' 
Acid phosphatase was the first tumor marker to be mea-
sured in blood. Although it is used as a marker of pros-
tatic carcinoma, serum levels are also elevated in many 
diseases of prostate, bone, and hematologic tissue. 
While serum acid phosphatase concentration is elevated 
in patients with prostatic carcinoma or infarction, it may 
also be increased merely with benign hypertrophy and 
after prostate massage. Recent studies demonstrate that 
levels are not significantly increased after routine rectal 
examination. Although of limited use as a screening test, 
the assay may be useful in staging, prognostication dur-
ing hormonal therapy, and in making clinical decisions. 
Rectal examination remains the best screening test for 
carcinoma of the prostate. 
CZarcinoma o f the prostate is the second most common 
causeof cancer death among American men, with42,000 
new cases and 17,000 deaths per year (1,2). It has been 
estimated that 30% of new cases are potentially curable 
(3,4). Digital examination of the prostate has been the 
standard screening test, but it has been reported that as 
many as80% of patients have advanced disease on initial 
presentation (5). Thus, prostatic carcinoma, although 
often detected early as a nodule in the gland, continues 
to be a diff icult problem for the primary care physician. 
Civen the difficulties of anatomic tumor detection, 
attention has turned to the use of tumor markers in this 
condit ion, and the measurement of serum acid phos-
phatase (SAP) has been widely used. Al though assay 
methodology has advanced in recent years, several 
problems remain in using SAP as a marker both for 
screening and corroborat ion of diagnosis. This is well 
illustrated by the fol lowing case report. 
Case Report 
A 70-year-old white man presented with fatigue, a 40-
pound weight loss, bone pain, and polyuria of 6-12 
months' durat ion. His past medical history included dia-
betes mellitus type II control led with diet and chlorpro-
pamide 500 mg daily, coal miner's pneumoconiosis, and 
hypothyroidism, for which he was receiving desiccated 
thyroid. In 1974, he had undergone cholecystectomy, 
vagotomy, and pyloroplasty for cholelithiasis and a 
duodenal ulcer. 
Physical examination disclosed pallor and tenderness of 
the sternum and left ribs. The prostate was enlarged and 
the right lobe was indurated. There was mild distal sen-
sory neuropathy. 
Hemoglobin was 9.5 g/d l and the leukocyte count was 
8400/cu mm with 36% polymorphonuclear forms, 10% 
bands, 30% lymphocytes, 16% monocytes, 1 % eosino-
phils, 4% atypical lymphocytes, 1 % metamyelocytes, 1% 
myelocytes, and 1 % promyelocytes. The platelet count 
was 70,000/mm3. Urinalysis disclosed 1+ protein and 2+ 
glucose reactions,2 red blood cells, and4 leukocytes per 
high powered field. Electrolyte concentrations were 
normal, fasting blood glucose was 300 mg/d l , calcium 
was 9.2 mg/d l wi th an albumin of 4.0 g /d l , and phos-
phate was 4.0 mg/d l . The alkaline phosphatase was 185 
u / l (normal: 35-115), serum aspartate aminotransferase 
(SCOT) waslO u/L (normal: 9-33), and lactic dehydroge-
nase was 1106 u/L (normal: 106-290). The acid phospha-
tase assayed by thymolphthalein monophosphate sub-
strate was 21.8 u/L (normal: 0-0.7). 
Al though chest and left rib roentgenograms were nor-
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mal, a '^mTC methylene diphosphonate bone scan re-
vealed increased activity in the left lower ribs, a ^smTC 
sulfur co l lo id l iver/spleen scan demonstrated non-
visualization of the left lobe of the liver and a defect on 
the medial aspect of the spleen. Based on clinical diag-
nosis of carcinoma o f the prostate with bone metastases, 
transurethral resection of the prostate was performed. 
The tissue diagnosis was benign prostatic hypertrophy. 
Subsequent bone marrow biopsy revealed malignant 
histiocytosis. 
Discussion 
Acid phosphatase activity (EC 3.1.3.2) refers to the ability 
o fa group of enzymes to hydrolyze phosphate esters in 
an acid environment. In 1924, the activity was first discov-
ered in erythrocytes, and in 1935, intermittent surges of 
acid phosphatase activity originating f rom the prostate 
was demonstrated in the urine of men. From 1936 to 
1942, Gutman (6) studied serum acid phosphatase in 
human disease and found high levels in patients with 
prostatic carcinoma, particularly those with bone metas-
tases. I n this way, the measurement of serum acid phos-
phatase as the first tumor marker was established. In 
1941, Huggins (7) published his classic paper demonstrat-
ing that the prostatic epithel ium is under hormonal con-
trol and that in patients with prostatic cancer, castration 
and estrogen administration lower SAP, whi le andro-
gens raise the level. These observations form the basis 
for modern hormonal therapy. 
Whi le much is known 
enzymes in vi tro, their 
about the activity of these 
in vivo funct ion is unknown, 
because all in vitro studies have used artificial substrates 
in a hostile acid environment. Acid phosphatase is pres-
ent in all tissues and body fluids. Gram for gram, the 
normal prostate contains a thousand times more of the 
enzyme than any other tissue. In the prostate, the 
enzyme is found in the epi thel ium and lumenwhere i t i s 
primarily a secretory product. In the reticuloendothelial 
system, acid phosphatase is a lysosomal enzyme that 
accounts for the activity in the liver and spleen. Other 
cells containing significant quantities include osteo-
clasts, granulocytes, and platelets (8). 
Polyacrylamide gel electrophoresis has demonstrated 
the heterogenicity of the acid phosphatases f rom var-
ious tissues (Table 1). By means of isoenzyme analysis, it 
can be demonstrated that in prostatic carcinoma metas-
tatic to bone the elevated SAP is due to prostatic acid 
phosphatase, whi le in other bone disease, including 
metastases f rom nonprostatic carcinoma, the SAP origi-
nates f rom osteoclasts. Sensitive techniques demon-
strate low SAP activity in normal persons. Plasma con-
tains fraction 5, while serum contains fractions 3 and 5. 
Therefore, osteoclasts and platelets rather than prostate 
cells account for normal SAP activity. This cumbersome 
technique is not readily available for clinical use. 
Clinical enzymatic assays employ a phosphate ester sub-
strate which when hydrolyzed by phosphatase in the 
patient's serum yields a colorimetrically measurable 
product. Substrates used include phenylphosphate (King 
Armstrong units), B-glycerol phosphate (Bodansky units), 
n i t rophenyl phosphate, and more recently, thymol-
phthalein phosphate (international units). The last is the 
most popular substrate used at present and probably the 
most specific for prostatic acid phosphatase isoenzymes 
(9). 
Since the development of antibodies to prostatic acid 
phosphatase in 1972, several immunoassays have been 
developed. These include competit ive binding radioim-
unoassay (RIA),enzymoimmunoassays, and immunohis-
tologic methods (10). 
The instability of SAP by enzyme assay has been a major 
drawback to its clinical use. When separated from the 
clot at room temperature, activity is attenuated in one to 
TABLE I 
Polyacrylamide Gel Electrophoresis 
slowest 
Isoenzyme 
fastest 
Tissue 
or ig in 
Gaucher's 
cells 
1 
tissue 
bound 
prostate, 
leukocytes 
platelets, 
other 
tissues 
prostate, 
other 
tissues 
osteoclasts, 
histiocytes 
modi f ied f rom Yam (8) 
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two hours but is well preserved when buffered to a pH of 
6.2 to 6.4. Because SAP concentration is altered not only 
by enzyme inactivation but also by the contr ibut ion of 
platelet enzyme, the ideal specimen is a fresh plasma 
sample buffered to a pH of 6.4 (8). Radioimmunoassay is 
not affected by enzyme instability. 
Acid phosphatase in nonprostatic disease 
Table II lists the major diseases that are accompanied by 
elevations in SAP. In bone disease other than metastatic 
prostatic carcinoma, acid phosphatase is of electropho-
retic group 5 and reflects osteoclastic activity. Alkaline 
phosphatase reflects osteoblastic activity. Both enzymes 
may be complementary for the early detection of bone 
metastases in breast cancer patients (11). Miscellaneous 
condit ions for which scanty data exist include mult iple 
myeloma, osteoporosis, osteogenesis imperfecta, and 
thyroid and renal osteopathy (12). 
The frequency of SAP elevation in Gaucher's disease 
depends upon the substrate used; it approaches 100% 
with phenylphosphate but only 20% with glycerol phos-
phate. Increased SAP has not been reported inTay-Sachs 
or Letterer-Siwe disease. 
The elevations in SAP induced by platelet lysis dur ing 
clott ing are usually small (approximately 0.15 lU /m l ) , 
unless thrombocytosis is present (13). Thrombocytosis 
does account for the elevated SAP in thrombocythemia, 
polycythemia vera, and chronic granulocytic leukemia. 
Increased concentrations found in patients with mye-
loid metaplasia and acute lymphoblastic leukemia, the 
lymphoprol i ferative disorders fail to produce elevations 
in SAP (14). Platelet lysis may produce mild elevations in 
thromboembol ic disorders. There are anecdotal reports 
of SAP elevations in liver disease and in the mult iple 
endocrine neoplasia syndrome (15). A familial defi-
ciency of lysosomal acid phosphatase has been reported 
that presents as failure to thrive in infancy (16). 
Acid phosphatase in prostatic disease 
While SAP activity in nonprostatic disease is fascinating 
from a biological viewpoint and essential to understand 
when levels in an individual patient are to be inter-
preted, the ult imate use of the assay is as a marker of 
prostatic carcinoma; indeed, assay methods have been 
directed toward this end. There remain, however, sev-
eral areas of confusion. 
In 1949, after Hock and Tessler (17) had observed discre-
pancies in the SAP of a patient who had undergone 
prostat ic massage and catheter izat ion for ur inary 
TABLE II 
Diseases Demonstrat ing Elevated SAP Activity 
Tissue % w i th elevated Max imum 
SAP elevation 
X upper l imi l 
of normal 
Prostate 
Mal ignant 
Benign 
Bone 
Localized 
Soft tissue extension 
Bone Metastases 
Nonprostat ic carcinoma • 
invading prostate 
I 
I n fa ra ion (12,13) 
Hypert rophy (11) 
0-25 
10-60 
80 
30-80 
4-5 
10 
19 
21 
33 
100 
50-100 
56 
90-100 
2 
6 
300 
2 
20-90 
Mal ignant 
Primary bone tumor 
Metastases 
Benign 
Paget's disease 
Hyperparathyroidism 
Reticulendothel ial System 
Mal ignant 
Mal ignant histiocytosis 
Benign 
Gaucher's disease 
Familial sea-blue 
histiocyte syndrome 
Nieman Picks 
Hematologic 
Leukocytes 
Myeloprol i ferat ive 
Lymphprol i ferat ive 
Platelets 
Idiopathic thrombocytopenic 
purpura 
modi f ied f rom Whi te (14) 
obstruct ion, they studied the effect of prostatic massage 
on the SAP of 20 patients with prostatic disorders. 
A l though a rise in SAP occured in 17 patients, only four 
achieved levels compatible with a diagnosis of prostate 
8 
10 
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carcinoma. However, the authors recommended that 
the determinat ion of SAP be delayed 24 hours after 
prostatic massage. Whi le this effect of massage has been 
corroborated by some (18,19) and appears to be accepted 
by many urologists (20), some recent authors (21) have 
fai led to f ind SAP elevations. These early studies 
employed assay methods now known to have poor 
reproducibi l i ty, especially at low normal levels (22). 
Nevertheless, the concept that routine rectal examina-
t ion with palpation of the normal prostate may cause 
elevations in SAP is widespread (23). Al though many 
recent studies refute this belief (20-25), it persists tena-
ciously as an aphorism taught to medical students. 
Some early authors concluded that a rise in SAP after 
rectal examination indicated prostatic carcinoma (26,27), 
but recent studies have also failed to corroborate this 
concept (20,24). One source of diff iculty in establishing a 
relationship between SAP levels and prostatic carcinoma 
is the wide random fluctuations which occur normally 
(20,28). In addi t ion, after transurethral resection of the 
prostate performed on patients either wi th benign 
hypertrophy or wi th carcinoma, SAP elevations of 150-
fold normal occur in the former, whi le no elevation is 
observed in those with malignancy. The difference 
could be due to more l imited resection of the carcino-
matous gland, but this variable has been acceptably con-
trol led. Very likely, the normally differentiated benign 
gland contains more phosphatase than does malignant 
tissue (29). 
It has been fairly well documented that infarction of the 
prostate can cause SAP to rise four to seven times nor-
mal. For example, 8.3% of patients with benign prostate 
hypertrophy were found to have elevated SAP; in all 
cases, infarction was documented histologically (30). 
Silber (31) reported elevated SAP in 30% of those with 
infarct ion. Many such patients present wi th acute outlet 
obstruction f rom the edema of infarction after a long 
history of prostatisin. It is likely that the hypertrophied 
gland outgrows its blood supply and releases acid phos-
phatase after infarction. 
Correlation with disease activity 
The studies of Huggins (7) in 1941 established the ratio-
nale for hormonal therapy of prostatic carcinoma and 
proposed a use for SAP as a marker of disease activity. 
However, only 75-85% of patients with an advanced 
stage of the disease have elevated SAP. The possible 
explanations for this variation, such as lack of secretion 
with di f ferent iat ion, low rates of secretion, or some bar-
rier to secretion enzyme, are all unproved. Moreover, 
SAP levels f luctuate randomly by 44-97%, making inter-
pretation very dif f icult (28). Ishibe (31) observed that the 
SAP in patients wi th stage B, C, and D carcinoma did not 
correlate with five-year survival during stilbertrol treat-
ment. The report has been corroborated but has not 
been correlated wi th histological grade, pr imari ly 
because of technical difficulties (32). However, 14% of 
patients with stage D disease reported by Griffiths (11) 
had normal SAP, and 90% were classified histologically as 
anaplastic. Furthermore, dur ing anti-adrogenic therapy, 
patients who exhibit a rise in SAP have a poor prognosis, 
whi le those in whom SAP falls have an improved prog-
nosis (31,32). In those who relapse after hormonal ther-
apy, a fall in SAP may correlate with survival, a 50% 
reduction in tumor mass, and relief of pain after chemo-
therapy (30). 
Acid phosphatase as a screening test * 
Unti l 1977, it was believed that elevated SAP by enzyme 
assay signified the presence of extracapsular, hence 
incurable, disease. That year, in a pilot study employing 
radioimmunoassay, Foti (33) concluded that over one-
half of all intracapsular disease could be detected. 
Therefore, SAP by radioimmunoassay was recommended 
as a screening procedure for intracapsular disease, even 
that undetectable by rectal examination, which was 
referred to as the "male PAP test" (34). 
Despite the diff iculties o f the reported studies, there are 
several points of agreement. Nevertheless, Foti's opt im-
istic report on the sensitivity for the diagnosis of intra-
capsular disease has not been conf i rmed. Al though the 
sensitivity of RIA is better than that of enzyme assays, it 
cannot signal the presence of intracapsular disease. 
Moreover, the specificity of RIA is only marginally better 
than that of the enzyme assay. 
The predictive value of SAP can be calculated using data 
for the incidence of prostate cancer, with the sensitivity 
and the specificity of RIA. The prevalence of the disease 
in the U.S. adult white male populat ion was 35 per 
100,000 in 1964. Radioimmunoassay sensitivity of 70% 
and specificity of 94%, determined by Foti (33) for all 
stages, can be used. Thus, the predictive value ofthis test 
wil l be 0.41% for the male populat ion; that is, one of 
every 244 subjects with elevated SAP wil l have prostatic 
carcinoma. Even if the specificity of the test reached 
100%, the cost of detecting one case of prostate carci-
noma by screening blood tests would be $36,000. Clearly, 
the test has little util ity for screening an unselected pop-
ulation. If used to screen only men 50 to 85 years of age, 
i.e., those at highest risk, the predictive value remains 
•See the Append ix fo ra discussion of the sensitivity and specificity of SAP by RIA 
and by enzyme assay. 
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o n l y 7%. To o b t a i n a p r e d i c t i v e va lue o f 50%, as accura te 
as the f l i p of a c o i n , even in this h igh risk p o p u l a t i o n , a 
sensi t iv i ty of 98% and a spec i f ic i ty of 99.5% w o u l d be 
r e q u i r e d (35). Statist ical cons ide ra t i ons a lone d e m o n -
strate t h e fu t i l i t y o f SAP sc reen ing tests. 
O n t h e o t h e r h a n d , i f t h e disease p reva lence is increased 
by f u r t h e r se l ec t i on , t h e p r e d i c t i v e va lue of SAP assay is 
i m p r o v e d cons ide rab l y . The p r o b a b i l i t y of ma l ignancy 
in a g i ven pros ta t ic n o d u l e is 50%. In th is p o p u l a t i o n , t he 
p r e d i c t i v e va lue o f a pos i t i ve test is 93% and o f a negat ive 
test is 84%. This i n f o r m a t i o n is par t i cu la r l y usefu l in eva l -
ua t ing a pa t ien t w i t h a n o d u l e w h e n need le b iopsy 
demons t ra tes b e n i g n h y p e r t r o p h y . If SAP is above no r -
ma l , t h e p r o b a b i l i t y of c a r c i n o m a is 93%, and t h e pa t ien t 
s h o u l d have a s e c o n d b iopsy . If t h e SAP is n o r m a l , t he 
p r o b a b i l i t y of b e n i g n disease is 84%, and m u l t i p l e b i o p -
sies are no t i nd i ca ted (36). 
G u i n a n (37) c o m p a r e d p rospec t i ve l y ten sc reen ing tests 
fo r prosta t ic c a r c i n o m a . The p o p u l a t i o n cons is ted o f 300 
m e n b e t w e e n t h e ages of 50 and 90 w h o w e r e e x a m i n e d 
fo r s y m p t o m s of u r i na ry o b s t r u c t i o n . Final d e t e r m i n e d 
p reva lence of c a r c i n o m a was 0.23%. Staging was no t 
r e p o r t e d . O n t h e basis o f recta l e x a m i n a t i o n , 85% of 
pat ients w e r e classif ied co r rec t l y . SAP by e n z y m e assay 
classi f ied 84% c o r r e c t l y , w h i l e SAP by RIA was on l y 70% 
accura te . The reasons fo r t h e p o o r sensi t iv i ty and spec i -
f ic i ty of RIA in th is s tudy are unc lear . Rectal e x a m i n a t i o n 
in th is s tudy was p e r f o r m e d by a u ro log i s t , and pat ients 
w e r e se lec ted because they had s y m p t o m s of disease. 
The qua l i f i ca t ions of t h e exam ine r may exp la in t h e 
s u p e r i o r accuracy o f t h e recta l e x a m , b u t t h e s ta teo f t h e 
pat ients w o u l d be e x p e c t e d to e n h a n c e t h e e f f i c i ency of 
all tests. W h i l e t h e p r o b l e m of a s y m p t o m a t i c pa t ien ts is 
no t addressed in th is s tudy , t h e recta l e x a m i n a t i o n is 
c lear ly t h e s imp les t , least cost ly , most re l iab le sc reen ing 
test avai lab le. 
L i n d h o l m (38) ques t ions the very c o n c e p t o f de tec t i ng 
in t racapsular disease. He argues tha t such a smal l t u m o r 
focus s h o u l d no t be e x p e c t e d t o raise SAP above t h r e s h -
o l d w h e n the neop lasm p roduces less e n z y m e o n a 
g r a m - f o r - g r a m basis than the n o r m a l o r h y p e r t r o p h i c 
g l and . M o r e o v e r , spec i f ic i ty o f t he test is no t pe r fec t ; t he 
secreted e n z y m e is d i l u t e d in f ive l i ters o f b l o o d and 
t h e n measured in a n o n p h y s i o l o g i c e n v i r o n m e n t . W h i l e 
SAP may be of some u t i l i t y in s tag ing , p rognos t i ca t i ng 
d u r ing t he rapy , and c l in ica l dec is ion m a k i n g , it is i r re le -
vant to d iagnosis . 
Appendix 
The util i ty of a test for screening purposes is a funct ion of its 
predictive value, which is dependent upon its sensitivity and 
specificity as well as the prevalence of the disease in the popu-
lation to be screened (38). 
Table III defines the relevant statistics. In the evaluation of a 
diagnostic test, the initial step is to determine how of ten the 
test is abnormal in a populat ion wi th wel l -def ined disease; the 
sensitivity and specificity so determined are useful in compar-
ing tests to each other. In practice, however, the question is 
not whether the person wi th disease has an abnormal test but 
whether the person with the abnormal test has disease. In a 
populat ion wi th a low prevalence of disease, the positive pre-
dictive value depends more on prevalence and specificity than 
on sensitivity. 
The major studies of the sensitivity and specificity of SAP both 
by RIA and by enzyme assay in the diagnosis of prostatic 
carcinoma are chiefly impressive in the wide divergence of the 
data. Several recent reviewers have discussed immune metho-
dology (10,40,41,42,35), Whi le most employ double antibody 
radioimmunoassay, Chu (43) used counter immunoelectro-
phoresis, an assay known to be less sensitive (10). To improve 
specificity, most assays use human prostatic f lu id as a sou ree of 
antigen. Chu (43) used malignant prostatictissueasa sourceof 
antigen, although there is no evidence foran acid phosphatase 
specific for malignancy. The concept of a unique prostate-
specific acid phosphatase is unproven, for low levels of SAP by 
TABLE III 
Calculation of the Predictive Value 
of a Single Laboratory Test 
Se 
Sp 
PVpos 
probability that a person with the disease has a 
postive test 
TP 
TP + FN 
probability thata person without the disease hasa 
negative test 
TN 
TN + FP 
probability that a person with a positive test 
has the disease 
TP 
TP-i- FP 
(Se) (P) 
Se 
Sp 
PVpos 
P 
TP 
FP 
TN 
FN 
(Se)(P) + (1-Sp)(1-P) 
sensitivity 
specificity 
positive predictive value 
prevalence of the disease in the population 
true positive 
false positive 
true negative 
false negative 
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RIA are detectable in women and prostatectomized men (34). 
However, the diff iculty may be technical, as Lindholm (38) 
found no cross-reactivity wi th acid phosphatase derived f rom 
platelets, erythrocytes, Gaucher's disease, and nonprostatic 
carcinoma. 
Sensitivity and specificity are interdependent and their calcu-
lation is based on data including the presumed upper l imit of 
normal. Published studies are frequently not comparable 
becausethese lec ted"normal " populat ions differ. Foti(33) set 
the upper l imit of normal above that of the entire normal 
contro l group. Grif f i ths (34) chose as a threshold value the 
mean plus two standard deviations based on a normal male 
control group. Persons wi th histologically conf i rmed benign 
hypertrophy comprised the control group of Bruce (44), whose 
upper l imit was in the 97.5 percenti le. Because Lindholm (38) 
established the upper l imit on the basis of a specificity of 94% 
and 97.5%, his sensitivities can be compared to those of others. 
He, too, used a group wi th benign hypertrophy as a control 
but, interest ingly,excludedthose with clinically suspected and 
histologically proved infarct ion. Griff i ths (34) excluded no one 
f rom his group wi th benign hypertrophy and found that, of 19 
wi th elevated SAP, 17 had histologic evidence of micro- or 
macro- infarct ion. Foti (33) failed to comment on infarction in 
his group with hypertrophy. Thus, the incidence of elevated 
SAP in uncomplicated benign hypertrophy is uncertain but 
probably very low. 
In addit ion to the use of di f fer ing control populations, failure 
to include staging criteria contributes to the varying reliability 
reported for SAP assay as a diagnostic test for prostate carci-
noma. Understaging, which is common when clinically staged 
patients are subsequently pathologically staged, wi l l increase 
the apparent sensitivity for early disease (41). Of Lind holm's 98 
patients (38), 43 were staged pathologically. Whi le he found 
sensitivities of 22% and 29% in stages A and B, respectively, 
none of the seven pathologically staged patients in his group 
had a positive test, and none of those wi th a positive test were 
pathologically staged. Bruce (44) staged the group with intra-
prostatic disease by bimanual exam. Whi le Foti in his original 
paper made no comment on staging details, he later confirmed 
that he staged laparotomy for stage B disease (45). 
Aside f rom simple lack of specificity, the only other proposed 
etiology of false positivity is hyperl ipoidemia, which Griff iths 
(34) found in two of his normal control group. Whi le SAP was 
markedly elevated by RIA, the enzyme assay was normal. 
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